INTRODUCTION
Chemokines are members of a large and expanding family of proteins that mediate diverse functions ranging from the regulation of pro-inflammatory processes to proliferative control and angiogenesis [1, 2] . Biochemically the chemokine family is defined by the presence of variations of a conserved cysteine motif. The two most populous subfamilies each have four positionally conserved cysteine residues. The first of these has an intervening amino acid between the first two cysteine residues and is referred to as the CXC or α-chemokine family ; the second has these first two cysteine residues juxtaposed and is referred to as the CC or β-chemokine subfamily. There are two smaller subfamilies, the CXXXC and C families, that are currently represented by only single members. We have been most interested in the β-chemokine macrophage inflammatory protein 1α (MIP-1α) and have characterized this protein as an inhibitor of haemopoietic stem cell proliferation [3, 4] . In common with many other chemokines, MIP-1α is pleiotropic and displays other activities such as the chemoattraction of leucocytes and regulation of osteoclast function [5] .
Chemokines are known to interact with target cells by binding to members of the heptahelical G-protein-coupled receptor family [6] . Receptors for the CXC chemokines are referred to as CXCRs (currently five in number) and receptors for CC chemokines as CCRs (of which there are currently twelve). Chemokine receptor biology and biochemistry are complicated by this large number of receptors and the fact that many ligands bind to a number of different chemokine receptors and many receptors bind a variety of chemokine ligands. Thus CCR5, perhaps the most carefully studied of β-chemokine receptors because of its involvement in Abbreviations used : MIP, macrophage inflammatory protein ; PF4, platelet factor 4. 1 To whom correspondence should be addressed (e-mail g.graham!beatson.gla.ac.uk).
affinity for proteoglycans. Furthermore, we demonstrate that the alteration of acidic amino acid residues in MIP-1α influences the affinity of its interactions with heparin as these residues are progressively neutralized, leading to an enhanced binding affinity for heparin. Thus, with MIP-1α, aggregation is not a determinant of proteoglycan binding ; however, overall charge does seem to have a major role in the interaction. These results therefore add to our understanding of the nature of the interaction between MIP-1α and proteoglycans and suggests that the basic amino acids might not be the sole regulators of proteoglycan binding.
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HIV pathogenesis [7] , counts among its ligands MIP-1α, MIP-1β, RANTES and monocyte chemoattractant protein 2 [8, 9] , all of which are bound by other receptors. MIP-1α, for example, will bind to CCR 1, CCR 3 (in the mouse), CCR 5 and D6 [9, 10] . Some subtlety in receptor-ligand interactions has been demonstrated by studies indicating the ability of chemokine receptors to discriminate between their many ligands and to mount ligand-specific effects on this basis [11] . In addition, evidence has recently been presented that demonstrates the ability of a receptor to mount different responses to the same ligand depending on concentration [12] .
Two biochemical features of MIP-1α, and other chemokines, can potentially further complicate the nature of the interaction between chemokines and their receptors. First, many chemokines spontaneously and non-covalently self-aggregate [13, 14] . This self-aggregation is dynamic and reversible and the extent of aggregation is determined by the concentration of the monomeric chemokine molecules. Thus, whereas MIP-1α at a concentration of 100 µg\ml is predominantly in a dodecameric form, it can aggregate to even higher-order structures at concentrations beyond this [13] . We and others have demonstrated charged residues to be a key to this self-aggregation and have generated a number of non-aggregating mutant versions of MIP-1α [15] [16] [17] . Our studies on the non-aggregating mutants of MIP-1α indicate that they have identical potency and efficacy in all assays examined, indicating that in these contexts MIP-1α interacts with its receptors as a monomer [15] . Although this is currently a widely held belief [18, 19] , there is evidence from studies on RANTES that it can interact with its receptors, in some contexts, as a dimer [20] . Additionally it has been demonstrated that chemokine receptors can dimerize on ligand binding [21, 22] and thus aspects of the role of aggregation in chemokine function and receptor binding remain to be elucidated.
The second biochemical feature of chemokines that might influence receptor binding is their ability to bind to proteoglycans. Chemokines bind to proteoglycans predominantly through clusters of basic amino acid residues. In many of the CXC chemokines these are likely to reside largely within the Cterminal α-helix [23, 24] ; however, the contribution from other basic amino acids is likely to determine the overall binding affinity for proteoglycans. With MIP-1α and MIP-1β, the proteoglycan-binding site has been mapped to a region between cysteine residues 3 and 4 that is highly conserved throughout the β-chemokine family [25] [26] [27] . This region is therefore likely to be generically involved in β-chemokine binding to proteoglycans. The role of proteoglycans in chemokine function is currently unclear. There is evidence of potentiating effects of proteoglycans on aspects of interleukin 8 function [28] and on the anti-HIV activity of RANTES [29, 30] . In addition, it has been demonstrated that proteoglycan-bound chemokines might facilitate leucocyte adhesion [31, 32] and that glycosaminoglycans can mediate cell-surface oligomerization of chemokines [33] . However, we and others have been unable to find any role for proteoglycan binding in MIP-1α or MIP-1β function [25, 26] .
One complicating feature of our previous studies has been the fact that the generation of variants of MIP-1α that do not bind proteoglycans has necessitated the neutralization of positive residues known to be involved in aggregation. Thus nonproteoglycan-binding MIP-1α does not aggregate beyond the dimeric form [25] . It therefore remains possible that, although there are no obvious effects of lack of proteoglycan binding on function, the combination of aggregation and proteoglycan binding might be required for the proper involvement of proteoglycans in MIP-1α function. Indeed, there is much evidence, from structural studies on the α-chemokine platelet factor 4 (PF4), for enhanced proteoglycan binding by the aggregated forms of this chemokine [34] [35] [36] . We have therefore undertaken a study to examine the impact of aggregation status on the proteoglycan binding of MIP-1α and show here, by using a range of approaches, that aggregation status is irrelevant to proteoglycan binding by this chemokine. In contrast with the lack of effect of aggregation status on heparin binding, this interaction does seem to be regulated by the overall charge of the MIP-1α molecule.
EXPERIMENTAL Reagents
The differentially aggregated murine MIP-1α mutants PM1, PM2 and PM3 were generated as described previously [15] . In brief, these mutants were produced by PCR-based mutagenesis and involved sequentially neutralizing the charges on C-terminal acidic amino acid residues. Thus PM1 had a mutation replacing Glu-66 with a Gln residue, the PM2 mutation replaced Glu-66 and Asp-64 with Gln and Asn residues respectively, and the PM3 mutation replaced Glu-66, Asp-64 and Glu-60 with Gln, Asn and Gln residues respectively. These proteins were generated in bacterial systems and purified as described previously [15] . Wildtype murine MIP-1α and anti-(murine MIP-1α) antibodies were purchased from R&D Systems Europe Ltd (Oxford, U.K.). All chromatography materials were purchased from Amersham Pharmacia Biotech (Little Chalfont, Bucks., U.K.), with the exception of the heparin-agarose generated by reductive amination, which was purchased from Sigma-Aldrich (Poole, Dorset, U.K.). Soluble heparin was purchased from SigmaAldrich.
Heparin-affinity chromatography
Heparin-affinity chromatography was performed by FPLC using a 1 ml HiTrap heparin-affinity column (Amersham Pharmacia Biotech). The column was run at a flow rate of 1 ml\min and elution was achieved by developing a gradient between 0.1 M NaCl\0.02 M Tris\HCl (pH 7.6) and 2 M NaCl\0.02 M Tris\ HCl (pH 7.6) as outlined in the relevant Figure legends . In addition, heparin elution was performed by developing a gradient from 0 to 5 mg\ml soluble heparin in PBS. Protein elution was followed by A #)! measurement, Western blot analysis or specific ELISA for murine MIP-1α (see below).
Heparin-affinitychromatographywiththereductive-aminationgenerated heparin-agarose resin was performed essentially as described above but at a flow rate of 0.5 ml\min.
Gel-filtration chromatography
Differentially aggregated states of wild-type MIP-1α were isolated by using gel filtration. Specifically, an HR10\30 Sephacryl S-200 column was poured and equilibrated with a 1 mg\ml solution of BSA in PBS. This BSA was included in all runs to minimize the non-specific binding of MIP-1α to the gel-filtration matrix, which had hampered previous gel-filtration studies with this chemokine. The S-200 column was run at a flow rate of 0.5 ml\min, dilutions of murine MIP-1α were applied in a volume of 0.5 ml, and 1 ml fractions were collected and analysed for the presence of MIP-1α by ELISA. Sizing was performed by comparison with molecular mass standards (Sigma-Aldrich) as indicated in Figure 2 (upper panel).
Immunodetection of MIP-1α
ELISA MIP-1α was detected in column fractions by using a murine MIP-1α-specific ELISA kit supplied by R&D Systems Europe Ltd. In essence, detection was performed in accordance with the manufacturer's instructions, although considerable dilution of column fractions in PBS was required for them to generate quantifiable signals in the plate reader at A %&! .
Western blotting
Cross-linked MIP-1α was detected in heparin column elution fractions by Western blotting with a previously published method [37] and a polyclonal anti-(MIP-1α) antibody provided by R&D Systems Europe Ltd. In brief, SDS\PAGE [17.5 % (w\v) gel] was performed on 20 µl aliquots from the heparin column fractions and the gel was blotted to a PVDF membrane with a semi-dry blotter. The blots were blocked for 1 h with multiple changes of Blotto [PBS\0.1 % (v\v) Nonidet P40\5 % (w\v) powdered milk]. Blots were exposed to primary antibody in Blotto for 1 h and were subsequently washed in multiple changes of Blotto over 1 h. The secondary antibody was a horseradishperoxidase-conjugated rabbit anti-goat polyclonal antibody (Sigma-Aldrich) ; the blots were again exposed to this antibody in Blotto for 1 h. The blots were washed again in multiple changes of Blotto and finally with PBS\0.1 % (v\v) Nonidet P40 before the detection of antibody with the enhanced chemiluminescence system (ECL2 ; Amersham Pharmacia Biotech). Results were revealed by exposing blots to X-ray film for various durations.
Cross-linking of murine MIP-1α
Cross-linking of differentially aggregated states of wild-type MIP-1α used the photoactivatable chemical cross-linking method of Fancy and Kodadek [38] . In brief, murine MIP-1α was suspended at a concentration of 100 µg\ml in PBS ; 100 µl of this solution was cross-linked in the presence of 10 µl of 1 mM histidine, 10 µl of 25 mM ammonium persulphate and 10 µl of 1.25 mM tris-bipyridylruthenium(II) dication (Sigma-Aldrich). This mixture was illuminated with a mercury lamp for 1 s and immediately diluted with 970 µl of PBS and removed from exposure to light. Cross-linking was assessed by Western blotting as outlined above and elution of the cross-linked protein from heparin-affinity columns followed by Western blotting of individual fractions.
RESULTS

Disaggregated mutants of MIP-1α display altered affinity for heparin
In our initial attempts to investigate the effect of aggregation on proteoglycan binding by MIP-1α, we tested the ability of differentially aggregated mutant variants of murine MIP-1α to bind to a heparin-affinity column. As we have described previously [15] , these mutants were generated by the sequential neutralization of C-terminal acidic amino acid residues, resulting in stable tetrameric (PM1), dimeric (PM2) and monomeric (PM3) mutants. Each was brought to a concentration of 100 µg\ml, at which they were known to be present in their respective aggregated states, and 500 µl was applied to a HiTrap heparin-affinity column as described in the Experimental section. A gradient from 0.1 to 0.5 M NaCl was developed, with a subsequent step to 2 M NaCl ; 1 ml fractions were collected. As shown by the elution profiles in Figure 1 , there was a clear difference in the position in the gradient at which elution of the differentially aggregated variants was seen. Thus PM3 was eluted at approx. 0.45 M NaCl, PM2 at 0.4 M NaCl and PM1 at 0.34 M NaCl. Given the alterations in acidic amino acids in these mutants, there are two alternative explanations for the apparent inverse relationship between aggregation status of MIP-1α and affinity for proteoglycans. First, it is possible that aggregation has an impact on heparin binding by MIP-1α, with higher-order aggregates having a lower affinity. Secondly, overall affinity for heparin might not be dictated solely by the presence of basic amino acid residues but might also involve a contribution from acidic amino acid residues. The progressive neutralization of acidic residues in PMs 1-3 might therefore increase the affinity for heparin. If this were the case it would argue that the overall charge on MIP-1α might be a significant determinant of heparin binding affinity.
Generation of differentially aggregated states of wild-type MIP-1α
To attempt to discriminate between these two options and to clarify the basis for the differential binding of the three disaggregated mutants, we have produced solutions containing differentially aggregated MIP-1α states by progressive dilution of the wild-type molecule. As shown in Figure 2 (upper panel), it is possible, by progressively diluting wild-type MIP-1α, to produce
Figure 3 Cross-linked MIP-1α aggregates show indistinguishable binding to heparin-affinity columns
Upper panel : murine MIP-1α was cross-linked with the photoactivatable cross-linking agent tris-bipyridylruthenium(II) chloride. The extent of cross-linking was confirmed by SDS/PAGE and Western blotting with a murine MIP-1α-specific polyclonal antibody. Lower panel : 1 ml of the mixture of cross-linked MIP-1α aggregates was applied to a HiTrap heparin affinity column and eluted with an increasing NaCl concentration. Fractions of 250 µl were collected ; eluted protein was detected by Western blotting as described above. Lane MW, molecular mass markers.
predominantly tetrameric, dimeric and monomeric forms. Thus at concentrations of 5 µg\ml MIP-1α is predominantly tetrameric, with some evidence of higher-order aggregates, at 1 µg\ml it is dimeric and at 500 ng\ml or less it is almost entirely monomeric. We have previously reported human MIP-1α to require dilution below 100 ng\ml for complete disaggregation [15] , suggesting that human MIP-1α aggregates are more strongly held together than their murine counterparts. These differentially aggregated forms of MIP-1α were then applied to heparinaffinity columns and eluted with an NaCl gradient from 0.1 to 0.6 M NaCl. As shown in Figure 2 (lower panel), no effect of aggregation was seen on the affinity of binding to heparin : all three differentially aggregated dilutions were eluted at 0.36 M NaCl. This salt concentration is similar to that required for the elution of PM1 and wild-type MIP-1α from heparin-affinity columns ( Figure 1 , and results not shown). Thus these results suggest that the differences in affinity seen with the differentially aggregated mutants in Figure 1 might relate more to the progressive neutralization of acidic amino acid residues, and the effective alteration of overall charge, than to the aggregation status of the MIP-1α.
Cross-linked MIP-1α also does not show differential affinity for heparin
One potential problem with the above results is that the aggregated status of the different dilutions of MIP-1α might be affected by the dilutions or buffers encountered during the passage through either the gel-filtration column or the heparinaffinity column. It was for this reason, and to minimize overall dilutions, that we used the pre-gel-filtration column dilutions rather than the post-gel-filtration column fractions (Figure 2 , upper panel) in our heparin binding analyses (Figure 2 , lower panel). Nevertheless, to address this concern more carefully we sought to generate stable, covalently cross-linked, variants of MIP-1α whose aggregated status would be unaffected by the dilution or composition of the elution buffer. Most cross-linking reagents are inappropriate for cross-linking MIP-1α, frequently being too short to cover the inter-monomeric distances calculated from the crystal structure of the dimeric and tetrameric MIP-1α molecules (J. McLean, G. J. Graham and N. W. Isaacs, unpublished work). Recently, however, a novel cross-linking strategy involving the photolysis of tris-bipyridylruthenium(II) chloride has been described [38] . This cross-linking reagent has been very effective in allowing us to generate monomeric, dimeric and tetrameric species of MIP-1α along with some other higher-order aggregates ( Figure 3, upper panel) . This cross-linked mixture of differentially aggregated wild-type MIP-1α was applied to a heparin-affinity column and eluted with an NaCl gradient. As shown in Figure 3 (lower panel), SDS\PAGE and Western blotting showed no differences in the elution profiles of the differentially cross-linked MIP-1α variants, all of which were eluted from the heparin column at a median concentration of approx. 0.36 M NaCl, essentially identical with that for PM1 ( Figure 1 ) and the differentially aggregated MIP-1α preparations produced by dilution (Figure 2 ). This again suggests that there was no impact of aggregation status on heparin binding by wildtype MIP-1α. It should be mentioned that it is formally possible that the cross-linked species are capable of further non-covalent aggregation on the heparin matrix ; if so, this might confound interpretation of the present results. However, the studies of Hoogewerf et al. [33] indicate that, at the concentrations used in the present study, MIP-1α seems to be unable to aggregate beyond the dimeric state on heparin-affinity matrices, suggesting that further aggregation of the cross-linked species is unlikely. Furthermore, the coincidence of the elution points for the monomeric, dimeric and tetrameric species, seen in Figure 3 (lower panel), would argue that, if some further self-aggregation was occurring, it had no impact on the point of elution of MIP-1α from the column. This again argues against an effect of aggregation state on heparin binding by MIP-1α.
Heparin elution and the use of an alternative heparin-agarose matrix also suggest no effect of aggregation status on binding of MIP-1α to heparin
Given the ability of immobilized heparin to act as both an ionexchange matrix and a specific affinity matrix, it remains possible that it was predominantly the electrostatic\ion-exchange interactions that were being measured in these experiments and not the specific affinity interaction of MIP-1α with heparin. To examine this possibility we took two approaches. First, we
Figure 4 Elution with heparin confirms the indistinguishable heparin binding of differentially aggregated forms of wild-type MIP-1α
The differentially aggregated dilutions of MIP-1α described in Figure 2 (upper panel) were applied (500 µl) to a HiTrap heparin column and the MIP-1α was eluted by a 0-5 mg/ml gradient of soluble heparin. Fractions of 250 µl were collected and the elution of bound protein was monitored by MIP-1α specific ELISA (A 450 ). Note that the different peak heights in this examined the ability of soluble heparin, rather than salt, to release the differentially aggregated preparations from the heparin-affinity column. This is an elution condition that more specifically measures the affinity interaction between a ligand and a heparin-affinity resin. The differentially aggregated dilutions of MIP-1α, prepared as outlined above, were passed through a heparin-affinity column and eluted with a gradient from 0 to 5 mg\ml of soluble heparin in PBS. As shown in Figure 4 , wildtype MIP-1α and all three differentially aggregated preparations were eluted at the same point in the gradient at a concentration corresponding to approx. 3 mg\ml heparin. Although some further elution seemed to occur at 5 mg\ml heparin, this was not seen consistently ; indeed, heparin concentrations up to 10 mg\ml failed to mediate further chemokine elution from the heparin column. Secondly, we examined the binding and elution of the differentially aggregated variants with an alternative heparin-agarose matrix. This matrix was generated by reductive amination, which couples heparin to the agarose matrix through the N-terminus and leaves the remainder of the molecule free to interact in a more ' physiological ' manner than with other attachment methods, which typically anchor each heparin molecule to the matrix at multiple attachment sites [39] . It is likely that reductive amination results in a heparin matrix that functions more as a specific affinity matrix than as an ion-exchange matrix ; indeed, heparin matrices generated by ' reductive amination ' typically display less non-specific binding than matrices generated with other coupling methods [39] . As can be seen from Figure 5 (upper panel), even with this more specific affinity matrix there was no difference in the elution of the differentially aggregated variants, generated as outlined in Figure 2 (upper panel). All four differentially aggregated variants were eluted at an average concentration of approx. 0.4 M NaCl ; however, the elution peaks were broader than those in Figure 2 (lower panel), ranging between 0.36 and 0.45 M NaCl. Again, possible dilution or salt effects might have confused the analysis of this experiment ; we therefore also obtained further evidence for the equivalence of affinity interaction for the differentially aggregated variants by using the cross-linked aggregates generated as described above (see Figure 3, upper panel) . We applied the cross-linked aggregated variants to the heparin column generated by reductive
Figure 5 Differentially aggregated forms of MIP-1α display similar binding affinities for heparin matrices generated by ' reductive amination '
Upper panel : the differentially aggregated dilutions of MIP-1α described in Figure 2 (upper panel) were applied (500 µl) to a heparin-agarose column generated by ' reductive amination ' and the MIP-1α was eluted as described in the legend to Figure 2 (lower panel) except that the flow rate was 0.5 ml/min. As before, fractions of 250 µl were collected and the elution of bound protein was monitored by MIP-1α-specific ELISA (A 450 ). Symbols : $, undiluted (10 µg/ml) ; , 1 : 1 dilution (tetramer) ; i, 1 : 9 dilution (dimer) ; >, 1 : 19 dilution (monomer). FT, flow through. Lower panel : 1 ml of the cross-linked MIP-1α aggregates was applied to the heparin column generated by ' reductive amination ' and was eluted with increasing concentrations of NaCl. Fractions of 250 µl were collected and eluted protein was detected by Western blotting.
amination and showed, by using Western blotting, that the elution points for the monomeric, dimeric and tetrameric species were identical, peaking at approx. 0.36 M NaCl ( Figure 5, lower  panel) .
Together, these results again suggest that there was no effect of aggregation status of wild-type MIP-1α on heparin binding and further argues that this lack of effect was independent of whether the heparin matrix was acting as a weak anion exchanger or as a specific affinity matrix.
DISCUSSION
There has been much interest in the role of proteoglycans in chemokine function but as yet no general picture has emerged of the importance of this interaction. It is clear from a number of studies that, for certain chemokines, proteoglycan interactions are not essential for at least some aspects of function [25] [26] [27] . Nevertheless, there are results demonstrating a role for proteoglycans in regulating the function of some chemokines [28] [29] [30] [31] [32] [33] ; additionally, MIP-1α and RANTES are stored as macromolecular complexes associated with heparin sulphate in T-cell cytolytic granules [40] .
There have been several structure-function studies demonstrating a relationship between chemokine aggregation status and affinity for proteoglycans. Thus PF4 can exist in monomeric, dimeric and tetrameric forms and a range of studies have demonstrated the tetramer to have the highest affinity for proteoglycans [34] [35] [36] . This enhanced affinity is a consequence of the presence of a ring of positive charge round the tetramer owing to the precise alignment of the monomeric units in the PF4 tetramer. This relationship between aggregation status and proteoglycan affinity has not been studied for other chemokines. Here we have demonstrated that there is no evidence for an effect of aggregation on the affinity of the β-chemokine MIP-1α for heparin. The evidence of an inverse relationship between aggregation status and affinity for proteoglycans seen with the previously generated non-aggregating mutants (Figure 1) suggests that the simple presence of basic amino acid residues in MIP-1α might not be the only determinant of heparin binding affinity. We know that these non-aggregated mutants have folded correctly because they are functional in a range of bioassays [15] and, more importantly, because we have recently determined the crystal structure of these monomeric, dimeric and tetrameric mutants (J. MacLean, G. J. Graham and N. W. Isaacs, unpublished work). These structures are essentially identical with those previously described for MIP-1β [41] and other β-chemokines [42, 43] ; we are therefore confident that these mutants are fully functional and correctly folded. The progressive neutralization of acidic amino acid residues in PM1, PM2 and PM3 suggests that overall charge might be the ultimate factor in defining affinity of MIP-1α for heparin. Thus the highly acidic nature of the MIP-1α C-terminal tail is likely to be a contributing factor to the relatively weak interaction between this chemokine and proteoglycans.
What role can therefore be envisaged for interactions between MIP-1α and proteoglycans ? Our previous analyses, and those of others, have demonstrated the interaction between MIP-1α and proteoglycans to be of low affinity and, whereas other chemokines bind more avidly to proteoglycans, the affinity of these interactions is still considerably lower than that observed with receptor [44, 45] . Only PF4 has been reported to have an affinity for proteoglycans in the nanomolar range [34] [35] [36] 41] . This low affinity of chemokines for proteoglycans suggests that a simple involvement in ligand presentation to receptor, as has been proposed for the fibroblast growth factors [46] , is unlikely to be occurring. It might be more appropriate to view the interaction between proteoglycan-tethered ligand and receptor as one of ' donation ' from the lower-affinity proteoglycan to the highaffinity receptor, rather than presentation itself. It might therefore be that the role of proteoglycans in chemokine biology is to produce a local concentration of ligand that is given up to passing leucocytes on encountering appropriate receptors. Indeed, there is evidence that proteoglycans might mediate the oligomerization of chemokines, permitting the ' donation ' of aggregated chemokines to passing cells [33] . This proteoglycanmediated oligomerization might be important for the presentation of chemokine dimers, which might be relevant for aspects of receptor interactions [21, 22] . Such oligomerization on the proteoglycan matrix requires that local concentrations of chemokines in i o increase to exceed the threshold for aggregation. In our hands, with human MIP-1α, this threshold is 100 ng\ml, whereas with murine MIP-1α it is 500 ng\ml. Although these concentrations are relatively high, several studies in itro [47] [48] [49] [50] suggest that the generation of MIP-1α at concentrations up to 80 ng\ml from leucocytes is achievable and, given the very localized ' microenvironmental ' production thought to be occurring in i o, these cellular production levels are likely to result in very high local concentrations of MIP-1α, and other chemokines, that exceed the threshold for aggregation.
In summary, it seems from the present study that whatever the role of proteoglycans in MIP-1α function, unlike PF4, aggregation seems not to modulate it. The overall affinity of interaction seems to be determined by the combination of acidic and basic residues within MIP-1α, indicating that regions of chemokines other than those containing high densities of basic amino acid residues might be involved in determining the potency of proteoglycan binding.
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